1941 related articles for article (PubMed ID: 28819064)
21. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
22. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.
Ajona D; Ortiz-Espinosa S; Moreno H; Lozano T; Pajares MJ; Agorreta J; Bértolo C; Lasarte JJ; Vicent S; Hoehlig K; Vater A; Lecanda F; Montuenga LM; Pio R
Cancer Discov; 2017 Jul; 7(7):694-703. PubMed ID: 28288993
[TBL] [Abstract][Full Text] [Related]
23. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
24. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
25. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
26. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
28. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
29. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
Cheng B; Ding K; Chen P; Ji J; Luo T; Guo X; Qiu W; Ma C; Meng X; Wang J; Yu J; Liu Y
Cancer Commun (Lond); 2022 Jan; 42(1):17-36. PubMed ID: 34981670
[TBL] [Abstract][Full Text] [Related]
30. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
[TBL] [Abstract][Full Text] [Related]
31. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
32. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
33. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
[TBL] [Abstract][Full Text] [Related]
34. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Wang X; Yang X; Zhang C; Wang Y; Cheng T; Duan L; Tong Z; Tan S; Zhang H; Saw PE; Gu Y; Wang J; Zhang Y; Shang L; Liu Y; Jiang S; Yan B; Li R; Yang Y; Yu J; Chen Y; Gao GF; Ye Q; Gao S
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6640-6650. PubMed ID: 32161124
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
38. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
39. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]